EXPLAINER: How worried should we be about blood clots linked to AstraZeneca and J&J vaccines?

13 April 2021 - 17:51 By Ludwig Burger, Matthias Blamont and John Miller
subscribe Just R20 for the first month. Support independent journalism by subscribing to our digital news package.
Subscribe now
AstraZeneca said it was "working to understand individual cases and "possible mechanisms that could explain these extremely rare events".
AstraZeneca said it was "working to understand individual cases and "possible mechanisms that could explain these extremely rare events".

US regulators have recommended pausing the use of Johnson & Johnson's Covid-19 vaccine as they investigate rare blood clotting in six women, including one who died.

J&J also said it was delaying the rollout of its vaccine in Europe. US officials said the temporary halt is expected only to last a few days.

The move comes after Europe's drug regulator said it had found a possible link between AstraZeneca's Covid-19 vaccine and very rare blood clots in some adults who had received the shot.

Britain's health regulator has recommended people under the age of 30 get an alternative Covid-19 vaccine, if possible, rather than the AstraZeneca shot.

Experts said clotting risks for both vaccines remain extremely low and they are highly effective in providing protection against Covid-19, amid fears that reports of the rare side effects could deter people from getting their shots.

Here's what we know so far:


With both the AstraZeneca and Johnson & Johnson (J&J)vaccines, the reports involve extremely rare clotting, including a type of blood clot called cerebral venous sinus thrombosis (CVST), that were seen in combination with low levels of blood platelets, called thrombocytopenia.

A U.S. Centers for Disease Control and Prevention (CDC) committee plans to review the cases linked to the J&J vaccine, and the U.S. Food and Drug Administration (FDA) will review its analysis.

The agencies, like their European counterparts, described the clotting as extremely rare.

The European Medicines Agency (EMA) has said its vaccine side effects monitoring system, as of April 4, had received 169 reports of cases of CVST, or clots in blood vessels exiting the brain, and 53 cases of splanchnic vein thrombosis (SVT), or clotting in veins in the abdomen.

That's out of 34 million AstraZeneca vaccine doses administered in Britain and the European Economic Area over the past three months.

The EMA's safety committee carried out a review of 62 cases of CVST and 24 cases of SVT, of which 18 were fatal.

Most cases occurred within two weeks of the person receiving their first dose.

German vaccination officials, who recorded 29 cases of CVST in women aged 20 to 59 who received the AstraZeneca vaccine, said the occurrence rate in that group was 20 times higher within 16 days of vaccination than what would have typically been expected.

Germany's health ministry has said 1 to 1.4 cases of CVST would have been expected during that time.


In J&J's case, all six recipients were women between the ages of 18 and 48, and the symptoms occurred six to 13 days after vaccination. In total, more than 6.8 million doses of the Johnson & Johnson vaccine have been given in the United States through April 12.

Similarly, most of the cases reported in Europe have occurred in women under 60, though that could be misleading, since Germany and Britain say more women got AstraZeneca's shot than men.

Most cases occurred within two weeks of people getting the first AstraZeneca dose.


J&J said it was working closely with regulators and noted no clear causal relationship had been established between the events and its shot.

AstraZeneca said it was "working to understand individual cases and "possible mechanisms that could explain these extremely rare events".


The CDC is recommending pausing using J&J's single-dose vaccine "out of an abundance of caution" to ensure that the health care providers are aware of potential side effects and can plan for "proper recognition and management."

Britain's Medicines and Healthcare products Regulatory Agency, meanwhile, made its recommendation for an alternative vaccine to AstraZeneca's to be used for people under 30 after reviewing 79 cases of rare clotting coupled with low platelets, with 19 fatalities - 13 women and six men. Eleven of the deaths were of people under the age of 50 and three were under the age of 30.


In the United States, health officials said treatment of the blood clots with possible ties to the J&J vaccine differs from what might be considered standard in such situations.

"Usually, an anticoagulant drug called heparin is used to treat blood clots," they said. "In this setting, administration of heparin may be dangerous, and alternative treatments need to be given."

By contrast, German doctors and scientists investigating clotting associated with AstraZeneca shots have recommended that doctors give high concentrations of heparin, Fc receptor-blocking monoclonal antibody and intravenous immunoglobulin.


In its findings, the EMA said on March 18 that, on average, just 1.35 cases of CVST might normally have been expected among people under 50 within 14 days of receiving AstraZeneca's vaccine, whereas by the same cut-off date 12 cases had been recorded.

By comparison, four women out of 10,000 would get a blood clot from taking oral contraception.

British officials drew on statistics from the University of Cambridge's Winton Centre for Risk and Evidence Communication to explain their recommendations that young people get an alternative shot while older people can continue to get AstraZeneca's.

According to the Centre, the risk of serious harm due to vaccination falls the older people get and the number of admissions to intensive care units falls sharply thanks to vaccinations, boosting the AstraZeneca shot's benefit-to-risk ratio.

The Centre concluded that only 0.4 people for every 100,000 in the 50-59 age group would suffer vaccine-linked harm, while 95.6 ICU admissions per 100,000 people would be prevented.


The EMA, which said the benefits of using AstraZeneca's vaccine continue to outweigh any risks, said that unusual blood clots with low blood platelets should be listed as very rare side effects and countries should decide on how to proceed.

These may vary from nation to nation, the EMA said, depending on factors like infection rates and whether there are vaccine alternatives.


Among possible causes being investigated are that the vaccine triggers an unusual antibody in rare cases. So far, risk factors like age or gender have not been singled out.

German scientists at Greifswald University concluded in a paper published last week in the New England Journal of Medicine that the extremely rare cases of clotting with low platelets - something they are calling "vaccine-induced immune thrombotic thrombocytopenia" - are triggered by antibodies found in the affected patients following vaccination with AstraZeneca's shot.

A separate group of Norwegian scientists have made similar conclusions - that AstraZeneca's vaccine triggered an immune response that may have led to clotting in a small number of people - in their own article, also published in the New England Journal of Medicine.

Andreas Greinacher, an Greifswald expert on drug-induced immune responses, is, like the EMA, seeking clues about why in rare cases people developed clots and low platelets after getting the vaccine, while the vast majority did not.


subscribe Just R20 for the first month. Support independent journalism by subscribing to our digital news package.
Subscribe now